Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Stordal, Britta ^a,b   Hamon, Marion ^a   McEneaney, Victoria ^b   Roche, Sandra ^a   Gillet, Jean Pierre ^c   O'Leary, John J ^b   Gottesman, Michael ^c   Clynes, Martin ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BRCA1 PROTEIN; CARRIER PROTEIN; CISPLATIN; CTR1 PROTEIN; FOLATE BINDING PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE REDUCTASE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL LEVEL; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STRESS; UPREGULATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GLUTATHIONE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; OVARIAN NEOPLASMS; P-GLYCOPROTEINS; PACLITAXEL;

EID: 84863826350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040717     Document Type: Article

References (57)

1. Hennessy BT, Coleman RL, Markman M, (2009) Ovarian cancer. Lancet 374: 1371-1382.
2. Stordal B, Pavlakis N, Davey R, (2007) A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews 33: 688-703.
3. Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH, (1998) Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemotherapy & Pharmacology 41: 186-192.
4. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, et al. (1998) Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemotherapy & Pharmacology 41: 307-316.
5. Martin A, Clynes M, (1993) Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 11: 49-58.
6. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, et al. (2011) Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions. Mol Pharmaceutics 8: 2080-2088.
7. Richard Simon, Amy Lam, (2007) Analysis of Gene Expression Data Using BRB-Array Tools. Cancer Informatics 3: 11-17.
8. Wall R, McMahon G, Crown J, Clynes M, O'Connor R, (2007) Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples. Talanta 72: 145-154.
9. Suzukake K, Petro BJ, Vistica DT, (1982) Reduction in glutathione content of L-PAM resistant L1210 Cells confers drug sensitivity. Biochemical Pharmacology 31: 121-124.
10. Silber PM, Gandolfi AJ, Brendel K, (1986) Adaptation of a gamma-glutamyl transpeptidase assay to microtiter plates. Analytical Biochemistry 158: 68-71.
11. Cobbold C, Ponnambalam S, Francis MJ, Monaco AP, (2002) Novel membrane traffic steps regulate the exocytosis of the Menkes disease ATPase. Human Molecular Genetics 11: 2855-2866.
12. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T, (1993) In Vitro and in Vivo Reversal of Multidrug Resistance by GF120918, an Acridonecarboxamide Derivative. Cancer Research 53: 4595-4602.
13. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, et al. (1993) Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Research 53: 5225-5232.
14. Choudhuri S, Klaassen CD, (2006) Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters. International Journal of Toxicology 25: 231-259.
15. Chaudhary PM, Roninson IB, (1993) Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs. J Natl Cancer Inst 85: 632-639.
16. Bates SE, Medina-Perez WY, Kohlhagen G, Antony S, Nadjem T, et al. (2004) ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins. Journal of Pharmacology and Experimental Therapeutics 310: 836-842.
17. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T, (2007) The roles of copper transporters in cisplatin resistance. Cancer & Metastasis Reviews 26: 71-83.
18. Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, et al. (2006) Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin. Cancer Chemotherapy & Pharmacology 57: 84-90.
19. Takeyasu K, Tamkun MM, Renaud KJ, Fambrough DM, (1988) Ouabain-sensitive (Na+ + K+)-ATPase activity expressed in mouse L cells by transfection with DNA encoding the alpha-subunit of an avian sodium pump. Journal of Biological Chemistry 263: 4347-4354.
20. Liang XJ, Shen DW, Garfield S, Gottesman MM, (2003) Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Research 63: 5909-5916.
21. Townsend DM, Tew KD, Tapiero H, (2003) The importance of glutathione in human disease. Biomedicine & Pharmacotherapy 57: 145-155.
22. Rahman Q, Abidi P, Afaq F, Schiffmann D, Mossman BT, et al. (1999) Glutathione redox system in oxidative lung injury. Critical Reviews in Toxicology 29: 543-568.
23. Drew R, Miners JO, (1984) The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochemical Pharmacology 33: 2989-2994.
24. Stordal B, Davey R, (2009) A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy. Current Cancer Drug Targets 9: 354-365.
25. Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JR, et al. (1997) Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clinical Cancer Research 3: 1339-1346.
26. Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, et al. (1993) Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). International Journal of Cancer 53: 478-485.
27. Yang X, Page M, (1995) P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncology Research 7: 619-624.
28. Yang H, Zou W, Li Y, Chen B, Xin X, (2007) Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells. Cancer Biology & Therapy 6: 942-947.
29. Xu H, Choi SM, An CS, Min YD, Kim KC, et al. (2005) Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochemical & Biophysical Research Communications 328: 618-622.
30. Parekh H, Simpkins H, (1996) Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and-resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemotherapy & Pharmacology 37: 457-462.
31. Callaghan R, Crowley E, Potter S, Kerr ID (2008 March) Review/Drug Metabolism and Transport: P-glycoprotein: So Many Ways to Turn It On. Journal of Clinical Pharmacology.
32. Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC, et al. (2007) Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. International Journal of Cancer 120: 175-180.
33. Kim RB, (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metabolism Reviews 34: 47-54.
34. Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I, (1988) Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 27: 7607-7613.
35. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, et al. (2007) A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemotherapy & Pharmacology 59: 79-87.
36. Locke VL, Davey RA, Davey MW, (1999) Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells. British Journal of Haematology 106: 86-91.
37. Zhang X, Wu X, Li J, Sun Y, Gao P, et al. (2011) MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells. J Surg Oncol 104: 466-471.
38. Lee WK, Torchalski B, Kohistani N, Thevenod F, (2011) ABCB1 Protects Kidney Proximal Tubule Cells Against Cadmium-Induced Apoptosis: Roles of Cadmium and Ceramide Transport. Toxicological Sciences 121: 343-356.
39. Perego P, Romanelli S, Carenini N, Magnani I, Leone R, et al. (1998) Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Annals of Oncology 9: 423-430.
40. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, et al. (1998) Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. International Journal of Cancer 78: 454-463.
41. Sun B, Ranish JA, Utleg AG, White JT, Yan X, et al. (2007) Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics. Molecular & cellular proteomics 6[1] 141-9: 2007.
42. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, et al. (2006) Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Molecular & cellular proteomics 5[3] 433-43: 2006.
43. Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, et al. (2010) Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies. Gynecologic Oncol 117[2] 159-69: 2010.
44. Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, et al. (2006) Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 6[19] 5183-92: 2006.
45. Lee YY, Choi CH, Do IG, Song SY, Lee W, et al. (2011) Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea. Available.
46. DeLoia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, et al. (2011) Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecologic Oncology.
47. Gottesman MM, Hall MD, Liang XJ, (2009) Resistance to cisplatin results from multiple mechanisms in cancer cells. In: Bonetti A, Leone R, Muggia F, Howell SB, editors. pp. 83-88 editors. Platinum and Other Heavy Metal Compunds in Cancer Chemotherapy- Molecular Mechanisms and Clinical Applications. Humana Press.
48. Shen DW, Goldenberg S, Pastan I, Gottesman MM, (2000) Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. Journal of Cellular Physiology 183: 108-116.
49. Shen D, Pastan I, Gottesman MM, (1998) Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Research 58: 268-275.
50. Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, et al. (2002) Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
51. Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, et al. (2002) Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Haematology Research, Pembury Hospital, Pembury, Tunbridge Wells, Kent TN2 4QJ, United Kingdom. Available.
52. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, et al. (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. British Journal of Cancer 88: 1285-1291.
53. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, et al. (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Research 63: 6221-6228.
54. Ottone F, Miotti S, Bottini C, Bagnoli M, Perego P, et al. (1997) Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Br J Cancer 76[1] 77-82: 1997.
55. Pisano C, Morabito A, Sorio R, Breda E, Lauria R, et al. (2009) A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. Cancer Chemother Pharmacol 64[5] 1021-7: 2009.
56. Rischin D, Phillips KA, Friedlander M, Harnett P, Quinn M, et al. (2004) A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecologic Oncol 93[2] 417-21: 2004.
57. Stordal B, Pavlakis N, Davey R, (2007) Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review. Cancer Treatment Reviews 33: 347-357.